Inhibrx EPS - Earnings per Share 2020-2022 | INBX
Inhibrx eps - earnings per share from 2020 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Inhibrx Annual EPS |
| 2021 |
$-2.15 |
| 2020 |
$-3.01 |
| 2019 |
$-2.83 |
| Inhibrx Quarterly EPS |
| 2022-06-30 |
$-0.97 |
| 2022-03-31 |
$-0.80 |
| 2021-12-31 |
$-0.55 |
| 2021-09-30 |
$-0.54 |
| 2021-06-30 |
$-0.55 |
| 2021-03-31 |
$-0.51 |
| 2020-12-31 |
$-0.14 |
| 2020-09-30 |
$-0.77 |
| 2020-06-30 |
$-0.99 |
| 2020-03-31 |
$-1.11 |
| 2019-12-31 |
$0.00 |
| 2019-09-30 |
$-1.11 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.958B |
$0.007B |
|
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
|
